

Amendments to the Claims: This listing of claims will replace all prior versions, and listings, of claims in the application

Listing of Claims:

1. - 24. (Canceled)

25. **(Currently Amended)** An isolated recombinant polypeptide comprising:

(a) ~~the amino acid sequence SEQ ID NO:2[;]] or,~~

(b) ~~an immunogenic fragment of 15 or more contiguous amino acids of SEQ ID NO:2;~~

~~wherein the immunogenic fragment, when administered to a subject coupled to a suitable carrier or in a composition, which can include an adjuvant, is capable of inducing an antibody that specifically binds to said fragment within SEQ ID NO:2.~~

26. (Canceled)

27. **(Canceled)**

28. (Canceled)

29. **(Currently Amended)** ~~The isolated recombinant polypeptide of claim 25, wherein the polypeptide comprises~~ An isolated recombinant polypeptide comprising an immunogenic fragment of 15 or more contiguous amino acids of SEQ ID NO:2; wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include ~~coupled to a suitable carrier coupled to the polypeptide or in a composition which can include~~ an adjuvant, is capable of inducing an antibody that specifically binds to said fragment within SEQ ID NO:2.

30. (Canceled)

31. **(Currently Amended)** The isolated recombinant polypeptide of claim 25 29, wherein the immunogenic fragment ~~of (b)~~ comprises 20 or more contiguous amino acids of SEQ ID NO:2, wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include ~~coupled to a suitable carrier coupled to the polypeptide or in a composition which can include~~ an adjuvant, is capable of inducing an antibody that specifically binds to said fragment within SEQ ID NO:2.

32. (Previously Presented) The isolated recombinant polypeptide of claim 25, wherein the isolated recombinant polypeptide consists of SEQ ID NO:2.

33-34. (Canceled)

35. (**Currently Amended**) A fusion protein comprising the isolated recombinant polypeptide of claim 25.

36. - 39. (Canceled)

40. (**Currently Amended**) An immunogenic composition comprising the isolated recombinant polypeptide of claim 25 and a pharmaceutically acceptable carrier.

41. (Previously Presented) The immunogenic composition of claim 40, wherein the immunogenic composition further comprises at least one other *Neisseria meningitidis* antigen other than a polypeptide comprising SEQ ID NO:2.

42. (Canceled)

43. (Previously Presented) A method for inducing an antibody in a mammal comprising administering the isolated recombinant polypeptide of claim 25 to the mammal in an amount effective to induce an antibody.

44. - 47. (Canceled)

48. (**Canceled**)

49. (**Canceled**)

50. (**Currently Amended**) A fusion protein comprising the isolated recombinant polypeptide of claim 29.

51. (Previously Presented) An immunogenic composition comprising the isolated recombinant polypeptide of claim 29 and a pharmaceutically acceptable carrier.

52. - 56. (Canceled)

57. (**Currently Amended**) A fusion protein comprising the isolated recombinant polypeptide of claim 31.

- 58. (Canceled)
- 59. (Previously Presented) An immunogenic composition comprising the isolated recombinant polypeptide of claim 31 and a pharmaceutically acceptable carrier.
- 60. (Previously Presented) An immunogenic composition comprising the fusion protein of claim 35 and a pharmaceutically acceptable carrier.
- 61. (Previously Presented) An immunogenic composition comprising the fusion protein of claim 48 and a pharmaceutically acceptable carrier.
- 62. (Previously Presented) An immunogenic composition comprising the fusion protein of claim 50 and a pharmaceutically acceptable carrier.
- 63. (Previously Presented) An immunogenic composition comprising the fusion protein of claim 57 and a pharmaceutically acceptable carrier.
- 64. (**New**) The immunogenic composition of claim 40, further comprising an adjuvant.
- 65. (**New**) The immunogenic composition of claim 51, further comprising an adjuvant.
- 66. (**New**) The immunogenic composition of claim 59, further comprising an adjuvant.
- 67. (**New**) The immunogenic composition of claim 60, further comprising an adjuvant.
- 68. (**New**) The immunogenic composition of claim 61, further comprising an adjuvant.
- 69. (**New**) The immunogenic composition of claim 62, further comprising an adjuvant.
- 70. (**New**) The immunogenic composition of claim 63, further comprising an adjuvant.
- 71. (**New**) The isolated recombinant polypeptide of claim 29, wherein the polypeptide is coupled to a carrier.
- 72. (**New**) The isolated recombinant polypeptide of claim 31, wherein the polypeptide is coupled to a carrier.